ACIP amplia las indicaciones para la vacuna neumocócica conjugada 13-valente

De @pedsupersite Infectious Diseases in Children - ACIP amplía las indicaciones para la vacuna neumocócica... fb.me/26EJRU5e1

— ALCIBIADES BATISTA G (@albatistag) 21 de febrero de 2013

Tomado de Infectious Diseases in Children (@PedSuperSite en Twitter) - ACIP amplía las indicaciones para la vacuna neumocócica conjugada: 

Niños y adolescentes de 6 a 18 años con condiciones de alto riesgo para enfermedad neumocócica grave, deben recibir la vacuna antineumocócica conjugada 13-valente, aún cuando hayan recibido previamente la vacuna conjugada heptavalente.

ACIP toughens recommendations for PCV13

February 20, 2013

Some children and adolescents with certain high-risk conditions should receive the 13-valent pneumococcal conjugate vaccine, according to a recommendation from the CDC’s Advisory Committee on Immunization Practices.

Patients aged 6 to 18 years who require immunosuppressive medication, are immunocompromised, have cochlear implants, asplenia, HIV, cerebrospinal fluid leaks, chronic renal failure and nephrotic syndrome should receive PCV13 (Prevnar 13, Pfizer), regardless of having previously received 7-valent pneumococcal conjugate vaccine (Prevnar, Pfizer), according to the committee.

The committee’s recommendation followed a presentation on the vaccine’s use that was given by Tamara Pilishvili, MPH, of the Respiratory Diseases Branch, National Center for Immunizations and Respiratory Diseases at CDC.

Pilishvili said although the population of children who have these higher-risk conditions is small, they are at increased risk for severe disease. She added that the recommendation for the stronger wording harmonizes the ACIP recommendations with those recommendations for high-risk adults.

Disclosure: Pilishvili reports no relevant financial disclosures.